Novo, Lilly Fall as Trump Touts ‘Much Lower’ Ozempic Price

Lilly, Novo Slide as Trump Touts ‘Much Lower’ Ozempic Price

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Madison Muller and Naomi Kresge

October 16, 2025 at 10:45 PM UTC

Updated on

October 17, 2025 at 2:39 PM UTC

Novo Nordisk A/S and Eli Lilly & Co. shares fell after President Donald Trump said the price of the blockbuster diabetes drug Ozempic could come down to just $150 a month.

The US list price of Ozempic, which Trump called “the fat loss drug,” is roughly $1,000 for a month’s supply. Trump told reporters on Thursday that the cost of the drug, made by Novo, will soon be “much lower.” Lilly sells similar treatments, including Mounjaro and Zepbound.